Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division
Elevai Labs announces record-breaking sales for its Elevai Skincare division in 2024. The company reported $300K revenue in November 2024, exceeding the previous four months average by 65%. Monthly revenues were: July ($160K), August ($199K), September ($168K), and October ($198K).
The achievement follows transformational restructuring efforts by the new executive team implemented in Q3 2024, focusing on operational efficiency and a performance-driven culture. Key success drivers included sales culture transformation, optimized budgets, improved marketing strategies, and targeted training programs. The company reports reduced operating expenses while achieving higher revenue, demonstrating progress toward positive net profits.
Elevai Labs annuncia vendite da record per la sua divisione Elevai Skincare nel 2024. L'azienda ha riportato $300K di fatturato a novembre 2024, superando la media dei quattro mesi precedenti del 65%. I ricavi mensili sono stati: luglio ($160K), agosto ($199K), settembre ($168K) e ottobre ($198K).
Questo risultato segue gli sforzi di ristrutturazione trasformativa messi in campo dal nuovo team esecutivo attuati nel Q3 2024, con un focus sull'efficienza operativa e una cultura orientata alla performance. I principali fattori di successo hanno incluso la trasformazione della cultura delle vendite, l'ottimizzazione dei budget, strategie di marketing migliorate e programmi di formazione mirati. L'azienda segnala una riduzione delle spese operative mentre raggiunge ricavi più elevati, dimostrando progressi verso profitti netti positivi.
Elevai Labs anuncia ventas récord para su división Elevai Skincare en 2024. La empresa reportó $300K en ingresos en noviembre de 2024, superando en un 65% el promedio de los cuatro meses anteriores. Los ingresos mensuales fueron: julio ($160K), agosto ($199K), septiembre ($168K) y octubre ($198K).
Este logro sigue a los esfuerzos de reestructuración transformativa implementados por el nuevo equipo ejecutivo en el Q3 de 2024, centrados en la eficiencia operativa y una cultura orientada al rendimiento. Los principales impulsores del éxito incluyeron la transformación de la cultura de ventas, la optimización de presupuestos, estrategias de marketing mejoradas y programas de formación específicos. La empresa informa que ha reducido sus gastos operativos mientras logra mayores ingresos, lo que demuestra progreso hacia beneficios netos positivos.
Elevai Labs는 2024년 Elevai Skincare 부문의 기록적인 매출을 발표했습니다. 회사는 2024년 11월에 $300K의 수익을 보고하며, 이전 4개월 평균을 65% 초과하였습니다. 월별 수익은 다음과 같습니다: 7월 ($160K), 8월 ($199K), 9월 ($168K), 10월 ($198K).
이 성과는 2024년 Q3에 새로운 경영진이 시행한 조직 개편의 결과로, 운영 효율성과 성과 중심 문화를 중점적으로 다뤘습니다. 주요 성공 요인은 판매 문화 변화, 예산 최적화, 개선된 마케팅 전략, 그리고 목표 중심 교육 프로그램이 포함되었습니다. 회사는 수익 증가를 이루면서 운영 비용이 줄어들었다고 보고하며, 긍정적인 순이익을 향한 진전을 보여줍니다.
Elevai Labs annonce des ventes record pour sa division Elevai Skincare en 2024. L'entreprise a rapporté 300 000 $ de revenus en novembre 2024, dépassant la moyenne des quatre mois précédents de 65 %. Les revenus mensuels étaient : juillet (160 000 $), août (199 000 $), septembre (168 000 $) et octobre (198 000 $).
Cette réalisation fait suite à des efforts de restructuration transformationnelle mis en œuvre par la nouvelle équipe exécutive au T3 2024, se concentrant sur l'efficacité opérationnelle et une culture axée sur la performance. Les principaux facteurs de succès comprenaient la transformation de la culture de vente, l'optimisation des budgets, des stratégies marketing améliorées et des programmes de formation ciblés. L'entreprise annonce une réduction de ses frais d'exploitation tout en réalisant des revenus plus élevés, montrant des progrès vers des bénéfices nets positifs.
Elevai Labs gibt rekordverdächtige Verkaufszahlen für die Elevai Skincare-Division im Jahr 2024 bekannt. Das Unternehmen meldete 300.000 $ Umsatz im November 2024, was die durchschnittlichen Einnahmen der vorherigen vier Monate um 65 % übersteigt. Die monatlichen Einnahmen betrugen: Juli (160.000 $), August (199.000 $), September (168.000 $) und Oktober (198.000 $).
Dieser Erfolg folgt auf transformative Umstrukturierungsmaßnahmen des neuen Führungsteams, die im Q3 2024 umgesetzt wurden, mit einem Fokus auf Betriebseffizienz und einer leistungsorientierten Kultur. Zu den Schlüsselfaktoren des Erfolgs gehörten die Transformation der Vertriebskultur, optimierte Budgets, verbesserte Marketingstrategien und gezielte Schulungsprogramme. Das Unternehmen berichtet von niedrigeren Betriebskosten bei gleichzeitig höheren Einnahmen und zeigt Fortschritte in Richtung positiver Nettogewinne.
- Record monthly revenue of $300K in November 2024
- 65% increase compared to previous 4-month average
- Reduced operating expenses while increasing revenue
- Successful implementation of cost management initiatives
- None.
Insights
The record-breaking sales performance at Elevai Skincare demonstrates significant operational improvements, with November revenue reaching
The sequential monthly revenue data shows steady improvement: July (
The focus on cost management alongside revenue growth suggests improving operational leverage, though specific margin and profitability metrics weren't disclosed. The company's emphasis on efficient resource allocation and streamlined operations could lead to better bottom-line results, particularly important for a small-cap company with a market cap of
The transformation in sales culture and marketing strategy reveals a well-executed turnaround plan in the physician-dispensed skincare segment. The integration of marketing and sales objectives, coupled with targeted training programs, suggests a more sustainable growth model that could extend beyond the current holiday season momentum.
The
- Skincare Division Achieves New Sales Milestone, Enters Holiday Season with Strong Momentum
- Strategic Restructuring Efforts Contributes to Achieving Record Monthly Sales and Sets Stage for Positive Projections for Year-End Growth
NEWPORT BEACH, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (Nasdaq: ELAB) (“Elevai”, “Elevai Labs” or the “Company”), a diversified holding company, announces that its wholly owned subsidiary, Elevai Skincare Inc. (“Elevai Skincare”), has achieved a record-breaking month in sales for 2024, marking a significant milestone for the Company. This achievement underscores the success of transformational restructuring efforts led by Elevai Labs’ new executive team and the adoption of a performance-driven culture.
The milestone comes as the Elevai Skincare division heads into the holiday season with strong momentum, strengthened by strategic initiatives that have streamlined operations, enhanced productivity, and positioned the brand for continued growth. Elevai’s management expressed its appreciation for the hard work and dedication of the Elevai Skincare operations team and sales force, who have demonstrated resilience in adapting to the newly implemented performance-based culture.
Since taking leadership of Elevai Labs, the parent company of Elevai Skincare, in the third quarter of 2024, the new management team has prioritized operational efficiency, strategic sales growth, and a high-performance sales culture. These efforts culminated in the highest monthly revenue figures for Elevai Skincare in 2024, exceeding the previous four months average sales by
Key drivers of success include:
- Sales Culture Transformation: Performance-based incentives and a results-oriented environment have driven motivation and accountability across the sales team.
- Optimized Budgets and Marketing Strategies: Stringent budgeting and accountability measures have ensured efficient resource allocation. By prioritizing impactful campaigns, the sales team has strengthened relationships with core physician-dispensed channels and driven disciplined, sustainable growth.
- Integrated Marketing and Sales Objectives: Improved collaboration between marketing and sales teams has aligned campaigns with sales goals, enhancing lead generation and conversion outcomes.
- Targeted Training Programs: Comprehensive training programs for both the sales team and physician-dispensed customers have bolstered advanced product knowledge, improved patient recommendation strategies, and strengthened clinic partnerships.
Preliminary unaudited sales data for Elevai Skincare for November 2024 reflects revenue of
- July:
$160 K - August:
$199 K - September:
$168 K - October:
$198 K
Positioned for Continued Growth
Elevai Skincare’s strong performance aligns with the Company’s overarching goal of creating shareholder value through operational excellence and strategic growth across its subsidiaries. With strong momentum entering the holiday season, the Company is well-positioned to drive further success as it closes out the year.
About Elevai Labs, Inc.
Elevai Labs Inc. (NASDAQ: ELAB) specializes in medical aesthetics and biopharmaceutical drug development, focusing on innovations for skin aesthetics and treatments tied to obesity and metabolic health. The Company operates a diverse portfolio of three wholly owned subsidiaries across the medical aesthetics and biopharmaceutical sectors, Elevai Skincare Inc., Elevai Biosciences Inc., and Elevai Research Inc. For more information please visit www.elevailabs.com.
About Elevai Skincare Inc.
A subsidiary of Elevai, Elevai Skincare is a medical aesthetics company developing and commercializing cutting-edge physician-dispensed skin and hair care applications that focuses on science-backed applications for the physician-dispensed market, utilizing cutting-edge technologies to redefine skincare and hair care, including its stem cell exosome technology. For more information, please visit elevaiskincare.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These risks and uncertainties include, among others: Elevai’s limited operating history and historical losses; Elevai’s ability to raise additional funding to complete the development and any commercialization of its product candidates; Elevai’s dependence on the success of its product candidates EL-22 and EL-32; that Elevai may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Elevai’s ability to obtain, maintain and protect its intellectual property; Elevai’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies; and Elevai’s expectations regarding its growth, strategy, progress and the design, objectives and timing of its studies. These and other risks are described more fully in Elevai’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
IR Contact:
IR@ElevaiLabs.com
FAQ
What was Elevai Labs (ELAB) revenue in November 2024?
How much did Elevai Labs (ELAB) sales increase in November 2024?
What were Elevai Labs (ELAB) monthly revenues from July to October 2024?
When did Elevai Labs (ELAB) implement its new management restructuring?
